このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

ドナー幹細胞移植を受ける血液がん患者における移植片対宿主病の予防のためのヒトリゾチーム山羊乳

2026年11月9日 更新者:City of Hope Medical Center

標準骨髄破壊的同種造血幹細胞移植のレシピエントにおけるヒトリゾチーム山羊乳のランダム化パイロット研究

This phase I trial studies the side effects of human lysozyme goat milk in preventing graft versus host disease in patients with blood cancer undergoing a donor stem cell transplant. Sometimes the transplanted cells from a donor can cause an immune response against the body's own normal cells (call graft versus host disease). The goat milk in the study is from goats that have been genetically engineered to produce human lysozyme in the milk. Human lysozyme is a natural enzyme found in human milk and acts as an antimicrobial. Lysozyme is key to the digestive health of breast-fed human infants, since it helps the growth of beneficial gut bacteria and reduces the growth of bacteria that causes diarrhea and intestinal disease. Giving human lysozyme goat milk may reduce the rate of graft versus host disease in blood cancer patients undergoing a donor stem cell transplant.

調査の概要

詳細な説明

PRIMARY OBJECTIVES:

I. To evaluate the safety and feasibility of human lysozyme goat milk (hLZ) treatment by assessing:

Ia: Type, frequency, severity, attribution, time course and duration of adverse events, including diarrhea, bloodstream/intestinal infections.

Ib. Patients' ability to drink the specified volume (250 ml 3 x/day) of hLZ during the treatment period.

SECONDARY OBJECTIVES:

I. To compare the incidence and severity of adverse events (AE) among hLZ-treated and untreated patients, including diarrhea, bloodstream infections and intestinal infections.

II. To obtain preliminary estimates of gut microbiome diversity, as assessed by the Simpson Index, in hLZ-treated/untreated patients.

III. To compare gut microbiome diversity among hLZ-treated/untreated patients. IV. To obtain a preliminary estimate of the possible association between gut microbiome diversity and bloodstream infections.

V. To obtain a preliminary estimate of the possible association between gut microbiome diversity and acute graft versus host disease (GVHD) cumulative incidence, including time to onset.

VI. To characterize and compare GVHD inflammatory biomarkers (presence, level) among hLZ-treated and untreated patients.

VII. To characterize and compare urinary uindoxyl sulfate, tryptophan and kynurenine levels between hLZ-treated and untreated patients.

IX. To obtain a preliminary estimate of gut microbiome diversity and calorie intake.

X. To estimate overall survival (OS) cumulative incidence (CI) chronic GVHD of relapse/progression, and non-relapse mortality (NRM) at 100 days (excluding chronic GVHD), 6 months, 1 year and 2 years.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP A:

CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2, undergo fractionated total body irradiation (FTBI) on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per City of Hope (COH) standard operating procedure (SOP) in the absence of disease progression or unacceptable toxicity.

HLZ: Patients receive human lysozyme goat milk orally (PO) three times daily (TID) on days -8 to 28 in the absence of disease progression or unacceptable toxicity.

TRANSPLANT: Patients undergo stem cell transplant on day 0.

GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity.

GROUP B:

CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2 per COH SOP, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.

TRANSPLANT: Patients undergo stem cell transplant on day 0.

GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity.

After the completion of study treatment, patients are followed up for up to 30-100 days and then up to 2 years after transplant.

研究の種類

介入

入学 (実際)

52

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • California
      • Duarte、California、アメリカ、91010
        • City of Hope Medical Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

12年歳以上 (子、大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Documented informed consent of the participant and/or legally authorized representative

  • Willingness to be followed for the planned duration of the trial (2 years)

  • All subjects must have the ability to understand and the willingness to sign a written informed consent

  • Karnofsky performance status >= 60 per COH SOP

  • Patients must be undergoing allogeneic hematopoietic stem cell transplantation (alloHCT) for hematologic malignancies from matched related or matched unrelated donors with 8/8 (A, B, C, DRB 1) high resolution human leukocyte antigen (HLA) donor allele matching

  • Patients must be receiving a fractionated total body radiation (FTBI) based- myeloablative conditioning regimen; (acceptable conditioning regimens include total body irradiation [TBI] + cyclophosphamide or TBI + etoposide)

  • Ejection fraction measured by echocardiogram or multi gated acquisition scan (MUGA) > 50%

  • Diffusing capacity for carbon monoxide (DLCO) adjusted for hemoglobin or forced vital capacity (FVC) > 50% predicted

  • Total serum bilirubin < 2 times upper limit of normal

  • Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 x the upper normal limit

  • Alkaline phosphatase =< 2.5 x the upper normal limit

  • Measured creatinine clearance more than 60 mL/min

  • Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through 90 days after the last dose of protocol therapy

    • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)

Exclusion Criteria:

  • Failure of research participant to understand the basic elements of the protocol and/or the risks/benefits of participating in this pilot study. A legal guardian may substitute for the research participant
  • Research participants receiving any other investigational agents
  • Research participants with presence of other active malignancy within 2 years of study entry. Participants with history of prior malignancy treated with curative intent who achieved complete remission (CR) more than 2 years before study entry are eligible. This exclusion rule does not apply to non-melanoma skin tumors and in-situ cervical cancer
  • Research participants having any uncontrolled illness including ongoing or active infection. Research participants with known active hepatitis B or C infection; research participants who are human immunodeficiency virus (HIV) seropositive based on testing performed within 4 weeks of enrollment; research participants with any signs or symptoms of active infection, positive blood cultures, or radiological evidence of infections
  • Refusing to use contraception up to 90 days post-HCT
  • Pregnant and/or breast feeding if a female recipient
  • Lactose intolerance or intolerance to milk products
  • In the opinion of the principal investigator (PI), the participant has a condition that will preclude them from complying with study treatment

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:支持療法
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Group A (conditioning, goat milk, transplant, prophylaxis)

CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.

HLZ: Patients receive human lysozyme goat milk PO TID on days -8 to 28 in the absence of disease progression or unacceptable toxicity.

TRANSPLANT: Patients undergo stem cell transplant on day 0.

GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity.

Given IV

他の名前:
  • シトキサン
  • CTX
  • (-)-シクロホスファミド
  • 2H-1,3,2-オキサザホスホリン、2-[ビス(2-クロロエチル)アミノ]テトラヒドロ-、2-オキシド、一水和物
  • カルロキサン
  • シクロホスファミダ
  • シクロホスファミド
  • シクロキサール
  • クラフェン
  • CP一水和物
  • サイクロセル
  • シクロスブラスチン
  • シクロブラスチン
  • シクロホスファム
  • シクロホスファミド一水和物
  • シクロホスファミダム
  • シクロホスファン
  • シクロホスファナム
  • シクロスチン
  • サイトホスファン
  • シトホスファン
  • フォスファセロン
  • ジェノクサル
  • ジェヌサル
  • レドキシン
  • ミトキサン
  • ネオサー
  • レビミューン
  • WR-138719

Given IV

他の名前:
  • デメチル エピポドフィロトキシン エチリジン グルコシド
  • EPEG
  • ラセット
  • トポサール
  • ベペシド
  • VP16
  • VP 16-213
  • VP-16
  • VP-16-213

Given PO

他の名前:
  • ラパミューン
  • 22989 年
  • ラパ
  • ラパマイシン
  • サイラ 9268A
  • WY-090217

Undergo allo-HCT

他の名前:
  • 同種造血細胞移植
  • HSC
  • HSCT
  • 同種幹細胞移植

Undergo FTBI

他の名前:
  • 分割定位放射線治療

Given human lysozyme goat milk PO

Given IV

他の名前:
  • 成長因子、組換えヒトケラチノサイト
  • ケピヴァンス
  • ケラチノサイト増殖因子、組換えヒト
  • 組換えヒトケラチノサイト増殖因子
  • rhKGF
  • rhuケラチノサイト成長因子

Given IV and PO

他の名前:
  • プログラフ
  • ヘコリア
  • FK506
  • フジマイシン
  • プロトピック
アクティブコンパレータ:Group B (conditioning, transplant, prophylaxis)

CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2 per COH SOP, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.

TRANSPLANT: Patients undergo stem cell transplant on day 0.

GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity.

Given IV

他の名前:
  • シトキサン
  • CTX
  • (-)-シクロホスファミド
  • 2H-1,3,2-オキサザホスホリン、2-[ビス(2-クロロエチル)アミノ]テトラヒドロ-、2-オキシド、一水和物
  • カルロキサン
  • シクロホスファミダ
  • シクロホスファミド
  • シクロキサール
  • クラフェン
  • CP一水和物
  • サイクロセル
  • シクロスブラスチン
  • シクロブラスチン
  • シクロホスファム
  • シクロホスファミド一水和物
  • シクロホスファミダム
  • シクロホスファン
  • シクロホスファナム
  • シクロスチン
  • サイトホスファン
  • シトホスファン
  • フォスファセロン
  • ジェノクサル
  • ジェヌサル
  • レドキシン
  • ミトキサン
  • ネオサー
  • レビミューン
  • WR-138719

Given IV

他の名前:
  • デメチル エピポドフィロトキシン エチリジン グルコシド
  • EPEG
  • ラセット
  • トポサール
  • ベペシド
  • VP16
  • VP 16-213
  • VP-16
  • VP-16-213

Given PO

他の名前:
  • ラパミューン
  • 22989 年
  • ラパ
  • ラパマイシン
  • サイラ 9268A
  • WY-090217

Undergo allo-HCT

他の名前:
  • 同種造血細胞移植
  • HSC
  • HSCT
  • 同種幹細胞移植

Undergo FTBI

他の名前:
  • 分割定位放射線治療

Given IV

他の名前:
  • 成長因子、組換えヒトケラチノサイト
  • ケピヴァンス
  • ケラチノサイト増殖因子、組換えヒト
  • 組換えヒトケラチノサイト増殖因子
  • rhKGF
  • rhuケラチノサイト成長因子

Given IV and PO

他の名前:
  • プログラフ
  • ヘコリア
  • FK506
  • フジマイシン
  • プロトピック

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Patients' ability to drink the specified daily amount of 750 ml human lysozyme goat milk (hLZ)
時間枠:from study initiation until up to 28 days post-transplant or until discharge, whoever comes first

In the safety lead-in phase, we are going to investigate if a patient can drink the daily amount of 750 ml of hLZ.. The actual volume of milk consumed per day will be measured using graduated cups and recorded on daily basis.

To calculate the average daily consumption, total volume of hLZ consumed by each patient for the whole inpatient stay will be divided by the total number of inpatient stay for that patient. Tolerable dose established based on the average daily hLZ consumption in the first 6 patients (safety lead-in) will be brought forward for additional study randomization.

from study initiation until up to 28 days post-transplant or until discharge, whoever comes first
Unacceptable toxicity
時間枠:Up to 28 days post-transplant or date of discharge

The modified Bearman Scale will be used to define unacceptable toxicity events. Unacceptable toxicity in a given patient is defined as either of the following that are considered at least possibly related to drinking hLZ milk: GI toxicity grade III or IV per Bearman scale or inability to consume hLZ milk for > 7 days.

Up to 28 days post-transplant or date of discharge
Adverse events
時間枠:Up to 100 days post-transplant

Incidence and severity of adverse events will be reported according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.03. Observed toxicities will be summarized in terms of type (organ affected or laboratory determination), severity, time of onset, duration, probable association with the study treatment and reversibility or outcome.

Up to 100 days post-transplant
Volume of hLZ consumed
時間枠:Up to 28 days post-transplant or date of discharge

Tolerability is defined as the ability to consume >= 150 ml/day over the treatment period.

Up to 28 days post-transplant or date of discharge

二次結果の測定

結果測定
メジャーの説明
時間枠
Cumulative incidence (CI) of chronic graft versus host disease (GVHD)
時間枠:At 6 months

Chronic graft versus host disease is scored according to NIH Consensus Staging. The first day of chronic GvHD onset will be used to calculate confidence interval (CI) incidence curves, with relapse/death prior to onset considered competing events. CI of chronic GVHD will be estimated using the method described by Gooley et al (1999).

At 6 months
Cumulative incidence (CI) of chronic GVHD
時間枠:At 1 year

Chronic graft versus host disease is scored according to NIH Consensus Staging. The first day of chronic GvHD onset will be used to calculate CI incidence curves, with relapse/death prior to onset considered competing events. CI of chronic GVHD will be estimated using the method described by Gooley et al (1999).

At 1 year
Cumulative incidence (CI) of chronic GVHD
時間枠:At 2 years

Chronic graft versus host disease is scored according to NIH Consensus Staging. The first day of chronic GvHD onset will be used to calculate CI incidence curves, with relapse/death prior to onset considered competing events. CI of chronic GVHD will be estimated using the method described by Gooley et al (1999).

At 2 years
CI of non-relapse mortality (NRM)
時間枠:At 100 days

Non-relapse mortality (NRM) is defined as death occurring in a patient from causes other than relapse. NRM is measured from start of treatment until non-disease related death, or last follow-up, whichever comes first. The cumulative incidence of NRM will be calculated reflecting relapse as a competing risk. CI of NRM will be estimated using the method described by Gooley et al (1999).

At 100 days
CI of NRM
時間枠:At 1 year

Non-relapse mortality (NRM) is defined as death occurring in a patient from causes other than relapse. NRM is measured from start of treatment until non-disease related death, or last follow-up, whichever comes first. The cumulative incidence of NRM will be calculated reflecting relapse as a competing risk. CI of NRM will be estimated using the method described by Gooley et al (1999).

At 1 year
CI of NRM
時間枠:At 2 years

Non-relapse mortality (NRM) is defined as death occurring in a patient from causes other than relapse. NRM is measured from start of treatment until non-disease related death, or last follow-up, whichever comes first. The cumulative incidence of NRM will be calculated reflecting relapse as a competing risk. CI of NRM will be estimated using the method described by Gooley et al (1999).

At 2 years
CI of relapse/progression
時間枠:At 100 days

The event is relapse/progression. Time to this event is measured from start of treatment. Death without relapse/progression is considered a competing risk. Surviving patients with no history of relapse are censored at time of last follow-up. CI of relapse/progression will be estimated using the method described by Gooley et al (1999).

At 100 days
CI of relapse/progression
時間枠:At 1 year

The event is relapse/progression. Time to this event is measured from start of treatment. Death without relapse/progression is considered a competing risk. Surviving patients with no history of relapse are censored at time of last follow-up. CI of relapse/progression will be estimated using the method described by Gooley et al (1999).

At 1 year
CI of relapse/progression
時間枠:At 2 years

The event is relapse/progression. Time to this event is measured from start of treatment. Death without relapse/progression is considered a competing risk. Surviving patients with no history of relapse are censored at time of last follow-up. CI of relapse/progression will be estimated using the method described by Gooley et al (1999).

At 2 years
Gut microbiome diversity
時間枠:Day - 8 +/- 3, day 0, day +7, day +14, day +21, day +28

Gut microbiome diversity will be assessed by the Simpson Index and compared between hLZ-treated/untreated patients. Association between treatment and gut microbial diversity will be assessed by Fisher's Exact test.

Day - 8 +/- 3, day 0, day +7, day +14, day +21, day +28
CI of acute graft versus host disease (aGVHD)
時間枠:At 100 days

Acute graft versus host disease will be graded according to the Consensus Grading. The first day of acute GvHD onset at a certain grade will be used to calculate cumulative incidence curves for that GvHD grade; relapse/death prior to onset will be considered competing events. CI of aGVHD will be estimated using the method described by Gooley et al (1999). Association between gut microbial diversity (inverse Simpson index: high [> 4], intermediate [2-4], and low [< 2]) or treatment and CI of aGVHD will be assessed by Gray's test.

At 100 days
Incidence of bloodstream infections
時間枠:Up to 100 days

Incidence of bloodstream infections and infectious enterocolitis will be evaluated and a preliminary estimate of the association between gut microbiome diversity and bloodstream infections will be obtained. Association between gut microbial diversity (inverse Simpson index: high [> 4], intermediate [2-4], and low [< 2]) or treatment and CI of bloodstream infections will be assessed by Gray's test.

Up to 100 days
Overall survival (OS)
時間枠:At 100 days

Patients are considered a failure for this endpoint if they die, regardless of cause. The time to this event is the time from start of treatment until death, or last follow-up, whichever comes first. OS will be estimated using the product-limit method of Kaplan and Meier.

At 100 days
Overall survival (OS)
時間枠:At 1 year

Patients are considered a failure for this endpoint if they die, regardless of cause. The time to this event is the time from start of treatment until death, or last follow-up, whichever comes first. OS will be estimated using the product-limit method of Kaplan and Meier.

At 1 year
Overall survival (OS)
時間枠:At 2 years

Patients are considered a failure for this endpoint if they die, regardless of cause. The time to this event is the time from start of treatment until death, or last follow-up, whichever comes first. OS will be estimated using the product-limit method of Kaplan and Meier.

At 2 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Karamjeet S Sandhu、City of Hope Medical Center

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年4月30日

一次修了 (実際)

2025年12月29日

研究の完了 (推定)

2027年3月23日

試験登録日

最初に提出

2019年10月14日

QC基準を満たした最初の提出物

2019年11月22日

最初の投稿 (実際)

2019年11月26日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月9日

最終確認日

2026年11月1日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する